Latest Industry Insights

In this interview, Patrick Brown tells us more about the evolution of NanoDrop over the past 20 years, highlights some of the most important improvements during this time and explores what the future may hold for the technology.

Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.

In this interview, Murat Kalayoglu, president and CEO of Cartesian Therapeutics discusses the company’s efforts to develop RNA-modified cell therapies that expand past oncology.

There is an inherent link between academia and industry that rarely gets the acknowledgement it deserves. Hear from a roundtable of PhD students on the impact that the collaborative relationship between academia and industry has on their work and the role that technology plays in the “Science Futures” initiative.

To learn more about the CMU Cloud Lab, the motivation behind the project and the benefits it will bring, Technology Networks spoke to Rebecca Doerge, PhD, dean, Mellon College of Science, Carnegie Mellon University, and Toby Blackburn, head of business development and research, Emerald Cloud Lab.

Technology Networks recently spoke with Richard Hague, PolarityTE’s chief executive officer and president, to learn more about the science behind SkinTE and how it could overcome some of the limitations associated with other chronic wound treatments.

Technology Networks spoke to Stefan Baier, head of food science at Motif FoodWorks, to learn more about the exclusive access to transformative plant-based food technologies the company has recently been granted. He also highlights the role plant-based foods play in protecting the environment and the importance of flavor and texture when developing plant-based foods.

Technology Networks spoke to Michael Heltzen, CEO and Dr. Kiana Aran, Chief Scientific Officer of Cardea Bio to find out more about the development of the SNP-Chip and how it has been used in a recent study to detect sickle cell disease and amyotrophic lateral sclerosis (ALS).

Technology Networks recently had the pleasure of speaking with Robert Hewitt, founder and manager of Biosample Hub, a unique platform designed to connect biotech and pharmaceutical companies with biobanks. Biosample Hub aims to help scientists obtain the samples they need to support the testing and development of novel therapeutics, diagnostics and vaccines, while establishing and maintaining biospecimen provenance information.

In this interview, Dr. Koh Meng Yong discusses the advantages of using lentiviral vectors and some of the applications they are enabling.